Clinical DevelopmentLast reviewed April 2026

Real-World Evidence(RWE)

Clinical evidence about the use, potential benefits, or risks of a medical product derived from analysis of real-world data.

Usage Examples

The supplemental NDA used RWE from an EHR-based external control arm to support the new indication.
FDA accepted RWE from a patient registry as supportive evidence for rare disease labeling change.

What is RWE?

Real-World Evidence (RWE) is clinical evidence derived from real-world data (RWD) sources including electronic health records, claims and billing data, product/disease registries, patient-generated data, and data from other sources (mobile devices, social media). FDA's RWE Framework (21st Century Cures Act) established formal pathways for using RWE to support regulatory decisions.

RWE has been used to support: new indications for approved drugs, post-approval study requirements, safety labeling changes, and in rare cases, new product approvals (typically for rare diseases where traditional RCTs are impractical). RWE quality depends on underlying data quality, analytical rigor, and study design appropriateness. FDA guidance outlines considerations for RWE submissions including data source assessment, study design, and statistical methods.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21ST CENTURY CURES ACT, FDCA SECTION 505F, PDUFA VI.

FDAEMAPMDA

When This Matters

The supplemental NDA used RWE from an EHR-based external control arm to support the new indication.
FDA accepted RWE from a patient registry as supportive evidence for rare disease labeling change.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

21ST CENTURY CURES ACTFDCA SECTION 505FPDUFA VI

Frequently Asked Questions

Rarely for new approvals, but increasingly yes for specific regulatory decisions — line extensions, safety labeling, rare disease indications. RCTs remain the gold standard for pivotal efficacy evidence in most approvals. RWE can support, complement, or substitute in specific contexts.

Electronic health records (EHRs), insurance claims data, disease and product registries, pharmacy records, patient-reported outcomes, wearable device data, and natural history study data. Each source has strengths and limitations for specific research questions.

FDA considers data source quality (completeness, accuracy, relevance), study design appropriateness (confounding control, missing data handling, outcome measurement), and statistical methodology. Pre-submission meetings are strongly recommended before RWE-based regulatory submissions.